Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib

BACKGROUND: Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors and resistance associated with BTK inhibition have not been characterized. Although only a small proportion of pat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Woyach, Jennifer A., Furman, Richard R., Liu, Ta-Ming, Ozer, Hatice Gulcin, Zapatka, Marc, Ruppert, Amy S., Xue, Ling, Li, Daniel Hsieh-Hsin, Steggerda, Susanne M., Versele, Matthias, Dave, Sandeep S., Zhang, Jenny, Yilmaz, Ayse Selen, Jaglowski, Samantha M., Blum, Kristie A., Lozanski, Arletta, Lozanski, Gerard, James, Danelle F., Barrientos, Jacqueline C., Lichter, Peter, Stilgenbauer, Stephan, Buggy, Joseph J., Chang, Betty Y., Johnson, Amy J., Byrd, John C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4144824/
https://ncbi.nlm.nih.gov/pubmed/24869598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1400029
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados